Related Experiment Video
Updated: Jul 3, 2026
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation
Junping Yu1, Yuri L Lyubchenko
1Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Summary
Researchers developed a novel nanotechnology tool to detect protein misfolding, a key factor in neurodegenerative diseases like Parkinson's. This tool revealed that alpha-synuclein dimers are static and may initiate protein aggregation.
Area of Science:
- Biophysics
- Nanotechnology
- Neuroscience
Background:
- Protein misfolding and aggregation are implicated in neurodegenerative diseases, including Parkinson's disease.
- The molecular mechanisms underlying protein misfolding and aggregation remain poorly understood.
- Understanding these processes is crucial for developing therapeutic strategies.
Purpose of the Study:
- To elucidate the molecular mechanisms of protein misfolding and aggregation.
- To develop a novel nanotechnology tool for detecting protein misfolding.
- To characterize the self-assembly of alpha-synuclein dimers.
Main Methods:
- Single molecule probing techniques.
- Atomic Force Microscopy (AFM) force spectroscopy.
- Characterization of alpha-synuclein dimer formation and dissociation.
Main Results:
- Developed a nanotechnology tool to detect protein misfolding.
- Detected protein misfolding through enhanced interprotein interactions.
- Measured the lifetime of alpha-synuclein dimers, finding them to be static and potential aggregation nuclei.
- Identified two distinct dissociation channels, suggesting multiple aggregation pathways.
Conclusions:
- Alpha-synuclein dimers are static and may serve as nuclei for protein aggregation.
- Protein aggregation can proceed through different pathways.
- The developed nanotechnology tool offers insights into protein misfolding and aggregation mechanisms relevant to neurodegenerative diseases.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...